Q-omics provides the consensus-scored GLIDR profile across patient tissues and cancer cell-line models. GLIDR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GLIDR is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, GLIDR RNA expression shows 17,724 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LUAD, and ACC as cancer lineages where GLIDR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLIDR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLIDR survival associations across molecular data types. GLIDR RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLIDR RNA expression–survival associations across cancer types. High GLIDR expression shows unfavorable associations in ACC and COAD, but favorable associations in MESO, KIRC, BRCA and LGG. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GLIDR RNA expression.
This table summarizes GLIDR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GLIDR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLIDR shows lower tumor expression in LUAD, KICH, BRCA, COAD and THCA and higher tumor expression in CHOL. The LUAD box plot shows higher GLIDR RNA expression in normal versus tumor tissue (log2 FC = −0.309, t-test p < 0.001).
This table shows molecular features associated with GLIDR in patient tissues and cancer cell lines. In patient samples, GLIDR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
